The AVT Advantage
AVT is the only pure-play ocular gene therapy company and is well positioned to develop highly efficacious and safe ocular products. The company's competitive advantages include:
- Products that will provide sustained and potentially lifelong therapy with a single treatment.
- A delivery system that will continuously bathe the back of the eye with therapeutic proteins.
- A first product that will block the growth of defective new blood vessels irrespective of the underlying cause. The competition blocks only one of at least 22 factors known to cause blood vessel formation in human eye diseases.
- A second product that will deliver a first-in-class retinal nurturing protein with the potential to revolutionize the treatment of RP and dry age-related macular degeneration.
- The only scale-up technology in the industry suitable for large scale manufacturing and commercialization.
- Outstanding management team and academic collaborations with leaders in the field.